Modified FLAG regimen in the management of refractory acute myeloid leukemia]

Long-jiang Yang,Fan-yi Meng,Bing Xu,Xiao-li Liu,Wei-yang Zheng,Yu Zhang,Fen Huang,Dan Xu,Jing Sun,Qi-fa Liu
DOI: https://doi.org/10.3321/j.issn:1673-4254.2003.10.021
2003-01-01
Abstract:To evaluate the therapeutic effect of modified FLAG regimen in the management of refractory acute myeloid leukemia (AML).Sixteen patients with refractory AML were divided into two groups. In modified FLAG regimen group (n=10), the patients received fludarabine (Flu, 50 mg/d, VDx5 d) and Ara-c (200 mg/d, VDx5 or 7 d). The regimen for classic FLAG group (n=6) consisted of Flu (50 mg/d, VDx5d), Ara-C (500 or 1,000 mg/d, VDx5d) and G-CSF (300 microg/d, x5 d, subcutaneously injected 4-6 hours before chemotherapy). Each patient received subcutaneous G-CSF (300 microg/d) when the white blood cell count was lower than 1.0x10(9)/L till the condition was corrected.The total complete remission(CR) rate of the 16 patients was 50% (8/16). Seven patients in modified group achieved CR (70%) and only one of the classic group did (17%, P<0.05). Episodes of infections were lower in modified group than in the classic group (50% vs 83%).Modified FLAG regimen is more likely than classic FLAG regimen to achieve CR and reduce infections in patients with refractory AML.
What problem does this paper attempt to address?